Compression and burst fractures: recognition, imaging, treatment, and the fracture that predicts the next one
A 78-year-old woman lifts a bag of groceries and feels something give in her back. The radiology report says “compression deformity of L1, age indeterminate.”
She is discharged with analgesics. Nobody orders a DXA. Eleven months later she is back with T12.
Common, underdiagnosed, and a predictor of death and of the next fracture
One in five patients with a new vertebral fracture has another vertebral fracture within a year.
19.2% (95% CI 13.6–24.8) in 2,725 placebo-arm women; a prevalent fracture raised the risk 5-fold. Lindsay 2001 Klotzbuecher 2000
What breaks, how much, and which fractures are not the simple kind

Wedge, biconcave and crush morphologies by degree of height loss. Original diagram after Genant 1993. Genant 1993
AO Spine–DGOU osteoporotic fracture types. Original diagram after Schnake 2018. Schnake 2018 Scherer 2025
Score the three domains and add them. Original diagram after Vaccaro 2005. Vaccaro 2005 Petfield 2011
Morphology types, neurological grade and modifiers. Original diagram after Vaccaro 2013. Vaccaro 2013
Textbook chapters reviewed: Vaccaro et al., Spine and Spinal Cord Trauma (Thieme, 2011). Williams 2011 Schmidt 2011 Blattert 2018
A 76-year-old woman falls from standing. CT shows an L1 fracture involving the superior end plate and the posterior wall with 25% canal retropulsion and no facet widening. MRI: intact posterior ligamentous complex. She is neurologically intact. How would you classify and score this injury?
| System | Answers | Use it when |
|---|---|---|
| Genant Genant 1993 | How much height is lost, and how many vertebrae | Reading radiographs, defining severe osteoporosis, choosing anabolic therapy |
| Denis three-column Denis 1983 | Which columns have failed | Bedside vocabulary: compression vs burst vs flexion-distraction |
| TLICS Vaccaro 2005 | Morphology + PLC + neurology as a score, and the approach | Communicating any thoracolumbar injury to the surgeon in one line |
| AOSpine thoracolumbar Vaccaro 2013 Kepler 2016 | A0–A4 / B / C morphology, N grade, M2 flags osteoporosis | Registries, research and high-energy or ankylosed-spine injuries |
| OF classification Schnake 2018 Blattert 2018 | Posterior wall, collapse, instability, and progression over time | Deciding between nonoperative care, augmentation and instrumentation in osteoporotic bone |
In every system the posterior wall and the neurological examination are the pivots; only the OF type is designed to be upgraded on follow-up imaging.


Is it acute, is the posterior wall intact, and is it osteoporosis at all?

MRI is the preferred advanced study in the expert consensus pathway; bone scan or CT are alternatives when MRI is not possible. Hirsch 2018 Expert 2023

| Feature | Favours osteoporotic | Favours malignant |
|---|---|---|
| Posterior cortex | Straight or retropulsed fragment | Convex, bulging posterior border |
| Pedicles and posterior elements | Normal signal | Abnormal signal, involvement |
| Soft tissue | None or thin haematoma | Epidural or paraspinal mass |
| Marrow pattern | Band-like low T1 signal, spared normal marrow | Diffuse replacement, inhomogeneous enhancement |
| Other vertebrae | Multiple compression fractures | Other focal lesions |
| Fluid or cleft | Fluid sign or vacuum cleft | Rare |
Non-fat-suppressed T2 signal alone does not discriminate. When in doubt, biopsy at the time of augmentation or before treatment. Jung 2003 Cuénod 1996

An 81-year-old woman presents with 5 days of severe midline pain after sitting down hard. Radiographs show a 30% anterior wedge of T12 that was not present on films from 2 years ago. She is neurologically normal and has no red flags. What imaging, if any, is most appropriate next?
Analgesia, mobilisation, and the truth about braces
Rigid brace, soft brace, or no brace
| Study | Design | N | Comparison | Key finding | Limitation |
|---|---|---|---|---|---|
Kim 2014 Kim 2014 | RCT, non-inferiority | 60 | No brace vs soft vs rigid, one-level fracture < 3 days | ODI at 12 weeks 36 vs 38 vs 34: no brace non-inferior; pain and compression progression identical | Small; Korean single centre |
Kato 2019 Kato 2019 | Multicentre RCT | 284 | Rigid vs soft brace for 12 weeks | No difference in vertebral compression at 48 weeks, pain, or quality of life | No no-brace arm |
Pfeifer 2004 Pfeifer 2004 | RCT | 62 | Spinomed orthosis 6 months vs none, chronic kyphosis | Back-extensor strength +73%, kyphosis −11%, pain −38% | Chronic patients; unblinded; industry device |
Rzewuska 2015 Rzewuska 2015 | Systematic review | 5 RCTs, 350 | Analgesics and orthoses vs control | Orthoses improved medium-term pain and disability vs nothing (SMD −1.5) | Very low to low quality evidence |
Pieroh (DGOU) 2023 Pieroh 2023 | Systematic review | 13 studies | Orthosis types and no orthosis | No superiority of any orthosis; where compared, non-rigid favoured | Heterogeneous, mostly low quality |
Two randomised trials show a rigid brace is no better than a soft brace, and no brace is non-inferior to either for pain, function and deformity. Orthoses may help some patients feel safer and, in chronic kyphosis, strengthen extensors.
Do not prescribe a rigid TLSO by reflex. Offer a soft or semi-rigid orthosis for comfort and confidence if the patient wants one, mobilise early, and reserve rigid bracing for the surgeon's specific plan.
Predictors from prospective and pooled data. Tsujio 2011 Muratore 2018 Ito 2002 Blattert 2018
Vertebroplasty, kyphoplasty, and a decade of contradictory trials
Transpedicular approach under fluoroscopy. Original diagram.
Vertebroplasty or kyphoplasty versus sham or conservative care
| Study | Design | N | Comparison | Key finding | Limitation |
|---|---|---|---|---|---|
Buchbinder 2009 Buchbinder 2009 | Sham-controlled RCT | 78 | Vertebroplasty vs sham, < 12 months | No difference at any time point; 3-month pain −2.6 vs −1.9 | Small; long symptom duration allowed |
INVEST (Kallmes) 2009 Kallmes 2009 | Sham-controlled RCT | 131 | Vertebroplasty vs simulated procedure | No difference in RDQ or pain at 1 month; 51% vs 13% crossed over | Sham included periosteal anaesthetic |
Vertos II (Klazen) 2010 Klazen 2010 | Open-label RCT | 202 | Vertebroplasty vs conservative, ≤ 6 weeks, MRI edema, VAS ≥ 5 | VAS difference 2.6 at 1 month, 2.0 at 1 year favouring vertebroplasty | Unblinded; 53% of screened had spontaneous relief |
VAPOUR (Clark) 2016 Clark 2016 | Sham-controlled RCT | 120 | Vertebroplasty vs placebo, < 6 weeks, NRS ≥ 7 | NRS < 4 at 14 days: 44% vs 21% | Sham without periosteal anaesthetic; industry grant |
VERTOS IV (Firanescu) 2018 Firanescu 2018 | Sham-controlled RCT | 180 | Vertebroplasty vs sham, acute | VAS differences 0.2–0.45 over 12 months, not significant | Sham included periosteal anaesthetic |
FREE (Wardlaw) 2009 Wardlaw 2009 | Open-label RCT | 300 | Kyphoplasty vs non-surgical care, ≤ 3 months | SF-36 PCS +7.2 vs +2.0 at 1 month; benefit fades by 12 months, pain still better at 2 years | Unblinded; industry funded |
VERTOS V (Carli) 2023 Carli 2023 | RCT vs active control | 80 | Vertebroplasty vs anaesthetic infiltration, chronic > 3 months with edema | 12-month VAS 3.9 vs 5.1; QUALEFFO better; disability not different | Small; control not a true sham |
Against a sham that anaesthetises the periosteum, vertebroplasty has shown no clinically important benefit; against conservative care or a skin-only placebo, it and kyphoplasty relieve pain faster, with the largest effects in severe pain of under 6 weeks. Effects fade by a year.
Augmentation is not routine care. Consider it for a patient with an MRI-confirmed acute fracture, severe pain despite adequate analgesia, and functional failure (cannot mobilise, hospitalised), after an honest discussion of the trials. It is not a treatment for the bone.
| Body | Year | Position |
|---|---|---|
| AAOS Esses 2011 | 2010 | Strong recommendation against vertebroplasty; weak recommendation that kyphoplasty is an option in neurologically intact patients |
| Cochrane Buchbinder 2018 | 2018 | High- to moderate-quality evidence of no important benefit over sham; harms cannot be excluded |
| ASBMR Task Force Ebeling 2019 | 2019 | No clinically significant benefit of vertebroplasty over placebo; insufficient evidence for kyphoplasty; routine use not supported; inform patients fully |
| Multispecialty pathway (RAND/UCLA) Hirsch 2018 | 2018 | Augmentation appropriate with positive advanced imaging and worsening symptoms or 2–4 unfavourable conditions; time since fracture less relevant |
| ACR Appropriateness Criteria Expert 2023 | 2022 | Scenario-based ratings; MRI preferred before treatment; augmentation may be appropriate for refractory painful acute fractures |
| NASS guideline Cho 2025 | 2025 | 29 evidence-graded questions on diagnosis and treatment; full guideline on the NASS website |
Specialty bodies read the same trials and reach different conclusions; the divergence tracks who wrote the guideline.
An 84-year-old man with an MRI-confirmed acute L2 wedge fracture (OF2) has been admitted for 6 days. Despite scheduled analgesics and physiotherapy he cannot stand, his pain is 8/10, and he has developed a sacral pressure area. Which statement best reflects the evidence?
When the osteoporotic fracture stops being a benign problem

| Study | Design | Result | Message |
|---|---|---|---|
| Wood 2003 Wood 2003 | RCT, 47 stable bursts, no deficit, 44 mo | Kyphosis and canal remodelling equal (39 → 22% vs 34 → 19%); pain and work similar; less disability, fewer complications without surgery | The stable burst is a nonoperative injury |
| Shen 2001 Shen 2001 | 80 patients, brace vs short-segment fixation, 2 y | Surgery: less pain to 3 months, equal by 6; correction lost; braced retropulsion 34 → 15%; charges four-fold | Early comfort, no lasting gain |
| Siebenga 2006 Siebenga 2006 | RCT, 34 patients, 4.3 y | Surgery: less kyphosis, better pain and function, more return to work | The dissenting trial: small, mixed types |
| Bailey 2014 Bailey 2014 | Equivalence RCT, 96 A3 bursts, TLSO vs none | Roland-Morris 6.8 vs 7.7 at 3 months: equivalent; 6 needed surgery | No brace equals a brace, for bursts too |
| Cantor 1993 Cantor 1993 | 18 bursts, intact posterior column, early ambulation | Kyphosis 19 → 20°; retropulsed bone resorbed; no neurological deterioration | The fragment remodels |
Spine Trauma Study Group: bracing 6–12 weeks is reasonable; either approach when surgery is chosen, posterior favoured in the elderly with poor bone. Sekhon 2011
All comparative data are retrospective; no randomised trial exists for surgery in osteoporotic burst fractures with deficit.


The strongest evidence in the pathway and the worst compliance: the drugs by name, what they do, and in what order
| Agent (US brand), class, dose | Pivotal trial | New vertebral fractures | Hip / nonvertebral | Watch for |
|---|---|---|---|---|
| Alendronate (Fosamax), bisphosphonate, 70 mg PO weekly | FIT, 2,027 women with prior VF, 3 y Black 1996 | 8.0% vs 15.0%, RR 0.53 (−47%) | Hip RH 0.49; wrist RH 0.52 | GI intolerance; AFF and ONJ with long use |
| Risedronate (Actonel; Atelvia delayed-release), bisphosphonate, 35 mg PO weekly | VERT-NA, 2,458 women, 3 y Harris 1999 | 11.3% vs 16.3% (−41%); −65% in year 1 | Nonvertebral 5.2% vs 8.4% (−39%) | As alendronate |
| Ibandronate (Boniva), bisphosphonate, 150 mg PO monthly | BONE, 2,946 women, 3 y Chesnut 2004 | 4.7% vs 9.6% (−62%) | No hip or nonvertebral benefit | Spine-only agent |
| Zoledronic acid (Reclast), bisphosphonate, 5 mg IV yearly | HORIZON, 7,765 women, 3 y Black 2007 | 3.3% vs 10.9%, RR 0.30 (−70%) | Hip 1.4% vs 2.5% (−41%); nonvertebral −25% | Acute-phase reaction; eGFR ≥ 35; AF signal |
| Denosumab (Prolia), RANKL antibody, 60 mg SC 6-monthly | FREEDOM, 7,868 women, 3 y Cummings 2009 | 2.3% vs 7.2%, RR 0.32 (−68%) | Hip −40%; nonvertebral −20% | Rebound fractures if stopped without a bisphosphonate |
| Raloxifene (Evista), SERM, 60 mg PO daily | MORE, 7,705 women, 3 y Ettinger 1999 | 6.6% vs 10.1%, RR 0.7 (−30%) | None | VTE RR 3.1; spine-only |
New morphometric vertebral fractures, drug versus placebo. Replete vitamin D and check renal function before any bisphosphonate.
| Agent (US brand), class, dose | Pivotal trial | New vertebral fractures | Hip / nonvertebral | Watch for |
|---|---|---|---|---|
| Teriparatide (Forteo; Bonsity), PTH 1–34, 20 µg SC daily, up to 2 y | Neer 2001, 1,637 women with prior VF, 21 mo Neer 2001 | 5% vs 14%, RR 0.35 (−65%) | Nonvertebral fragility 3% vs 6% (−53%) | Nausea, cramps, hypercalcaemia; not in Paget disease, open physes or prior skeletal radiation |
| Teriparatide vs risedronate | VERO, 1,360 women with severe osteoporosis, 2 y Kendler 2018 | 5.4% vs 12.0%, RR 0.44 | Clinical fractures HR 0.48 | Head-to-head win for the anabolic |
| Abaloparatide (Tymlos), PTHrP analogue, 80 µg SC daily, up to 2 y | ACTIVE, 2,463 women, 18 mo Miller 2016 | 0.58% vs 4.22% (−86%) | Nonvertebral HR 0.57 (−43%) | Less hypercalcaemia than teriparatide (3.4% vs 6.4%) |
| Romosozumab (Evenity), anti-sclerostin, 210 mg SC monthly × 12 | FRAME, 7,180 women, 12 mo Cosman 2016 | 0.5% vs 1.8% (−73%) | Clinical fractures −36%; nonvertebral NS at 12 mo | Then denosumab: vertebral fractures −75% at 24 mo |
| Romosozumab → alendronate | ARCH, 4,093 women with a fragility fracture, 2 y Saag 2017 | 6.2% vs 11.9% (−48%) vs alendronate alone | Hip −38%; nonvertebral −19% | Serious cardiovascular events 2.5% vs 1.9% in year 1: boxed warning Shoback 2020 |
Network meta-analysis of 69 trials: anabolics beat oral bisphosphonates for vertebral and clinical fractures at every level of baseline risk. Händel 2023
Apply it


A 74-year-old woman is diagnosed with an acute osteoporotic L2 compression fracture and treated nonoperatively. Her DXA T-score is −2.9 and this is her first fracture. Which statement about secondary prevention is best supported by evidence?
The fracture in front of you is the best predictor of the fracture you can still prevent.
Find it, classify it, treat the pain honestly, refer the ones that are not benign, and treat the bone.
1.Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320-3.
2.Kado DM, Browner WS, Palermo L, Nevitt MC, Genant HK, Cummings SR. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med. 1999;159(11):1215-20.
3.Lau E, Ong K, Kurtz S, Schmier J, Edidin A. Mortality following the diagnosis of a vertebral compression fracture in the Medicare population. J Bone Joint Surg Am. 2008;90(7):1479-86.
4.Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A. Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res. 2005;20(4):557-63.
5.Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137-48.
6.Schnake KJ, Blattert TR, Hahn P, Franck A, Hartmann F, Ullrich B. Classification of Osteoporotic Thoracolumbar Spine Fractures: Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU). Global Spine J. 2018;8(2 Suppl):46S-49S.
7.Blattert TR, Schnake KJ, Gonschorek O, Gercek E, Hartmann F, Katscher S. Nonsurgical and Surgical Management of Osteoporotic Vertebral Body Fractures: Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU). Global Spine J. 2018;8(2 Suppl):50S-55S.
8.Vaccaro AR, Oner C, Kepler CK, Dvorak M, Schnake K, Bellabarba C. AOSpine thoracolumbar spine injury classification system: fracture description, neurological status, and key modifiers. Spine (Phila Pa 1976). 2013;38(23):2028-37.
9.Jung HS, Jee WH, McCauley TR, Ha KY, Choi KH. Discrimination of metastatic from acute osteoporotic compression spinal fractures with MR imaging. Radiographics. 2003;23(1):179-87.
10.Tsujio T, Nakamura H, Terai H, Hoshino M, Namikawa T, Matsumura A. Characteristic radiographic or magnetic resonance images of fresh osteoporotic vertebral fractures predicting potential risk for nonunion: a prospective multicenter study. Spine (Phila Pa 1976). 2011;36(15):1229-35.
11.Muratore M, Ferrera A, Masse A, Bistolfi A. Osteoporotic vertebral fractures: predictive factors for conservative treatment failure. A systematic review. Eur Spine J. 2018;27(10):2565-2576.
12.Kim HJ, Yi JM, Cho HG, Chang BS, Lee CK, Kim JH. Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: a prospective randomized controlled non-inferiority trial. J Bone Joint Surg Am. 2014;96(23):1959-66.
13.Kato T, Inose H, Ichimura S, Tokuhashi Y, Nakamura H, Hoshino M. Comparison of Rigid and Soft-Brace Treatments for Acute Osteoporotic Vertebral Compression Fracture: A Prospective, Randomized, Multicenter Study. J Clin Med. 2019;8(2).
14.Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med. 2009;361(6):557-68.
15.Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med. 2009;361(6):569-79.
16.Klazen CA, Lohle PN, de Vries J, Jansen FH, Tielbeek AV, Blonk MC. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial. Lancet. 2010;376(9746):1085-92.
17.Firanescu CE, de Vries J, Lodder P, Venmans A, Schoemaker MC, Smeets AJ. Vertebroplasty versus sham procedure for painful acute osteoporotic vertebral compression fractures (VERTOS IV): randomised sham controlled clinical trial. BMJ. 2018;361:k1551.
18.Clark W, Bird P, Gonski P, Diamond TH, Smerdely P, McNeil HP. Safety and efficacy of vertebroplasty for acute painful osteoporotic fractures (VAPOUR): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10052):1408-1416.
19.Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet. 2009;373(9668):1016-24.
20.Buchbinder R, Johnston RV, Rischin KJ, Homik J, Jones CA, Golmohammadi K. Percutaneous vertebroplasty for osteoporotic vertebral compression fracture. Cochrane Database Syst Rev. 2018;11(11):CD006349.
21.Ebeling PR, Akesson K, Bauer DC, Buchbinder R, Eastell R, Fink HA. The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. J Bone Miner Res. 2019;34(1):3-21.
22.Hirsch JA, Beall DP, Chambers MR, Andreshak TG, Brook AL, Bruel BM. Management of vertebral fragility fractures: a clinical care pathway developed by a multispecialty panel using the RAND/UCLA Appropriateness Method. Spine J. 2018;18(11):2152-2161.
23.Carli D, Venmans A, Lodder P, Donga E, van Oudheusden T, Boukrab I. Vertebroplasty versus Active Control Intervention for Chronic Osteoporotic Vertebral Compression Fractures: The VERTOS V Randomized Controlled Trial. Radiology. 2023;308(1):e222535.
24.Uchida K, Nakajima H, Yayama T, Miyazaki T, Hirai T, Kobayashi S. Vertebroplasty-augmented short-segment posterior fixation of osteoporotic vertebral collapse with neurological deficit in the thoracolumbar spine: comparisons with posterior surgery without vertebroplasty and anterior surgery. J Neurosurg Spine. 2010;13(5):612-21.
25.Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41.
26.Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med. 2017;377(15):1417-1427.
27.Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230-240.
28.Anderson PA, Jeray KJ, Lane JM, Binkley NC. Bone Health Optimization: Beyond Own the Bone: AOA Critical Issues. J Bone Joint Surg Am. 2019;101(15):1413-1419.
29.Wu CH, Tu ST, Chang YF, Chan DC, Chien JT, Lin CH. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: A systematic literature review and meta-analysis. Bone. 2018;111:92-100.
30.Cho CH, Hwang SW, Mazanec DJ, O'Toole JE, Watters WC 3rd, Annaswamy TM. Guideline summary review: an evidence-based clinical guideline for the diagnosis and treatment of adults with osteoporotic vertebral compression fractures. Spine J. 2025;25(8):1670-1687.
31.Expert Panels on Neurological Imaging, Interventional Radiology, and Musculoskeletal Imaging, Khan MA, Jennings JW, Baker JC, Smolock AR, Shah LM. ACR Appropriateness Criteria® Management of Vertebral Compression Fractures: 2022 Update. J Am Coll Radiol. 2023;20(5S):S102-S124.
32.Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, Shamliyan T, Cooney TG, Clinical Guidelines Committee of the American College of Physicians. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Ann Intern Med. 2023;176(2):224-238.
33.Pieroh P, Spiegl UJA, Völker A, Märdian S, von der Höh NH, Osterhoff G. Spinal Orthoses in the Treatment of Osteoporotic Thoracolumbar Vertebral Fractures in the Elderly: A Systematic Review With Quantitative Quality Assessment. Global Spine J. 2023;13(1_suppl):59S-72S.
34.Zhang J, Wang G, Zhang N. A meta-analysis of complications associated with the use of cement-augmented pedicle screws in osteoporosis of spine. Orthop Traumatol Surg Res. 2021;107(7):102791.
35.Wiedl A, Geiger F, Eberl J, Wirries A, Hammad A. Mortality After Osteoporotic Vertebral Body Fractures: Cement Augmentation Versus Conservative Treatment—A Systematic Review and Meta-Analysis. Dtsch Arztebl Int. 2025;122(22):604-610.
36.Denis F. The three column spine and its significance in the classification of acute thoracolumbar spinal injuries. Spine (Phila Pa 1976). 1983;8(8):817-31.
37.Vaccaro AR, Lehman RA Jr, Hurlbert RJ, Anderson PA, Harris M, Hedlund R. A new classification of thoracolumbar injuries: the importance of injury morphology, the integrity of the posterior ligamentous complex, and neurologic status. Spine (Phila Pa 1976). 2005;30(20):2325-33.
38.Kepler CK, Vaccaro AR, Schroeder GD, Koerner JD, Vialle LR, Aarabi B. The Thoracolumbar AOSpine Injury Score. Global Spine J. 2016;6(4):329-34.
39.Black DM, Delmas PD, Eastell R. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-22.
40.Cosman F, Crittenden DB, Adachi JD. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N Engl J Med. 2016;375(16):1532-1543.
41.Wood K, Buttermann G, Mehbod A, Garvey T, Jhanjee R, Sechriest V. Operative compared with nonoperative treatment of a thoracolumbar burst fracture without neurological deficit. A prospective, randomized study. J Bone Joint Surg Am. 2003;85(5):773-81.
42.Bailey CS, Urquhart JC, Dvorak MF, Nadeau M, Boyd MC, Thomas KC. Orthosis versus no orthosis for the treatment of thoracolumbar burst fractures without neurologic injury: a multicenter prospective randomized equivalence trial. Spine J. 2014;14(11):2557-64.
43.Tezeren G, Kuru I. Posterior fixation of thoracolumbar burst fracture: short-segment pedicle fixation versus long-segment instrumentation. J Spinal Disord Tech. 2005;18(6):485-8.
Full reference list with DOI and PubMed links is available in the online references view.
Scan for the full reference list with PubMed links, the speaker notes handout, and this deck.